The amyloid antibody aducanumab is currently undergoing review by the FDA. The treatment would be the first disease-modifying drug to be approved for Alzheimer disease; however, a medical advisory committee recently convened by the FDA did not recommend approval, raising questions about whether the existing evidence of efficacy is sufficient.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings
European Journal of Nuclear Medicine and Molecular Imaging Open Access 27 December 2022
-
Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases
Journal of Neuroinflammation Open Access 08 September 2022
-
Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology
Journal of Neuroinflammation Open Access 07 February 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02477800 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02484547 (2020).
US National Library of Medicine. ClincialTrials.gov https://clinicaltrials.gov/ct2/show/NCT01677572 (2020).
Biogen. Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s disease. Investors.biogen.com https://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinue-phase-3-engage-and-emerge-trials (2019).
Food and Drug Administration. November 6, 2020 BLA 761178: Peripheral and Central Nervous System Drugs Advisory Committee Meeting. fda.gov https://www.fda.gov/media/143505/download (2020).
Food and Drug Administration. 21 314.126 Adequate and well-controlled studies. Electronic Code of Federal Regulations. https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=eebde221fa5a328fb93261e1fe8a849d&mc=true&n=pt21.5.314&r=PART&ty=HTML#se21.5.314_1126 (2020).
Food and Drug Administration. FDA Manual of Policies and Procedures MAPP 4151.8. fda.gov https://www.fda.gov/media/79353/download (2010).
Food and Drug Administration. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. fda.gov https://www.fda.gov/media/71655/download (1998).
Biogen. Update on FDA advisory committee’s meeting on aducanumab in Alzheimer’s disease. Investors.biogen.com https://investors.biogen.com/news-releases/news-release-details/update-fda-advisory-committees-meeting-aducanumab-alzheimers (2020).
Zhang, A. D., Schwartz, J. L. & Ross, J. S. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions 2008–2015. Milbank Q. 97, 796–819 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.F. has been a paid or unpaid consultant to Alector, Biogen, Genentech, Lilly, Lundbeck, Merck, Otsuka, Roche and Samus Therapeutics. H.F. also participated in a "Mock Advisory Committee" meeting with Biogen to review the presentation that was proposed to be given at the FDA Advisory Committee meeting discussed here. In the past month, A.G. has been a paid consultant to Samus Therapeutics.
Rights and permissions
About this article
Cite this article
Fillit, H., Green, A. Aducanumab and the FDA — where are we now?. Nat Rev Neurol 17, 129–130 (2021). https://doi.org/10.1038/s41582-020-00454-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-020-00454-9
This article is cited by
-
Loss of Direct Vascular Contact to Astrocytes in the Hippocampus as an Initial Event in Alzheimer’s Disease. Evidence from Patients, In Vivo and In Vitro Experimental Models
Molecular Neurobiology (2024)
-
Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease
Metabolic Brain Disease (2023)
-
Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings
European Journal of Nuclear Medicine and Molecular Imaging (2023)
-
Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases
Journal of Neuroinflammation (2022)
-
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential
Translational Neurodegeneration (2022)